This enduring activity provides highlights of a discussion between two experts in treating triple-negative breast cancer (TNBC) and aims. This activity aims to equip clinicians with up-to-date knowledge and practical strategies for integrating emerging data on TROP2-targeted antibody-drug conjugates into the management of advanced, inoperable, or metastatic TNBC, supporting evidence-based decision-making in anticipation of evolving treatment approvals and data presented at SABCS 2025. As a result of this educational activity, we anticipate that learners should be better able to: 1. Identify the role of TROP2-directed ADCs in metastatic TNBC treatment; 2. Compare the latest clinical data on available and emerging TROP2-targeting ADCs for the first-line treatment of patients with TNBC; and, 3. Discuss evidence-based strategies to optimize the selection of appropriate patients for first-line treatment with TROP2-targeting ADCs. Learners have access to downloadable materials for use in clinical practice.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 27 Trinity Place, Suite 185
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
- Commercial Support
-
ReleasedFeb 13, 2026
-
Last day to claim creditFeb 13, 2027 4 months left
-
Answers in CME Inc. (AiCME) From Theory to Practice: Integrating TROP2 ADCs in HR+/HER2- Breast Cancer
-
Answers in CME Inc. (AiCME) What s Now and What s Next for ADCs in NSCLC? Integrating HER2- and TROP2-Targeted Therapies Into the Evolving Treatment Landscape
-
Answers in CME Inc. (AiCME) Targeting TROP2 in Oncology: Pan-Tumor Insights and the Next Wave of ADC Innovation
